Table 1.
Baseline characteristics of the study population.
| Placebo | Policosanol | p value | |
|---|---|---|---|
| Total (n = 17) | Total (n = 15) | ||
| Age, years | 54.2 ± 6.5 | 51.3 ± 7.5 | 0.241 |
| Male, n (%) | 9 (53) | 8 (53) | |
| BMI | 21.9 ± 2.0 | 21.0 ± 1.5 | 0.143 |
| Total cholesterol, mg/dL | 222.1 ± 20.8 | 217.9 ± 14.8 | 0.521 |
| LDL-cholesterol, mg/dL | 133.4 ± 15.4 | 126.5 ± 10.8 | 0.159 |
| Triglycerides, mg/dLa | 74.0 [53.5–86.5] | 81.0 [60.0–115.0] | 0.118 |
| HDL-cholesterol, mg/dL | 66.1 ± 9.9 | 63.7 ± 11.4 | 0.532 |
| HDL efflux capacity, % | 15.9 ± 0.9 | 15.5 ± 0.8 | 0.231 |
| Apolipoprotein AI, mg/dL | 174.4 ± 19.2 | 174.0 ± 19.1 | 0.959 |
| Apolipoprotein AII, mg/dL | 35.5 ± 4.0 | 33.8 ± 3.2 | 0.202 |
| Apolipoprotein B100, mg/dL | 80.6 ± 12.1 | 88.0 ± 16.7 | 0.163 |
| Apolipoprotein B48, mg/dLa | 0.42 [0.23–0.54] | 0.55 [0.21–1.11] | 0.527 |
| HbA1c, % | 5.5 ± 0.2 | 5.5 ± 0.3 | 0.951 |
| Fasting blood glucose, mg/dL | 90.4 ± 8.9 | 91.1 ± 11.7 | 0.832 |
| hsCRP, mg/La | 0.35 [0.20–0.7] | 0.21 [0.18–0.52] | 0.170 |
Values are expressed as mean ± standard deviation, except for triglycerides, apolipoprotein B-48, and hsCRP (median [interquartile ranges]).
a
log-transformed prior to analysis. BMI, body mass index; LDL, low-density lipoprotein cholesterol; HDL, high-density lipoprotein; HbA1c, hemoglobin A1c; hsCRP, high sensitivity C-reactive protein.